25 results
424B5
CRNX
Crinetics Pharmaceuticals Inc
13 Sep 23
Prospectus supplement for primary offering
5:19pm
the Type C meeting in order to finalize the PATHFNDR-2 study protocol and initiate recruitment. We believe that, if successful, the PATHFNDR-2 trial
424B5
CRNX
Crinetics Pharmaceuticals Inc
11 Sep 23
Prospectus supplement for primary offering
4:09pm
the Type C meeting in order to finalize the PATHFNDR-2 study protocol and initiate recruitment. We believe that, if successful, the PATHFNDR-2 trial
424B5
CRNX
Crinetics Pharmaceuticals Inc
12 Aug 22
Prospectus supplement for primary offering
8:31am
design. We are awaiting the FDA’s final minutes from the Type C meeting in order to finalize the PATHFNDR-2 study protocol and initiate recruitment. We
424B5
CRNX
Crinetics Pharmaceuticals Inc
13 Apr 22
Prospectus supplement for primary offering
4:22pm
the FDA’s final minutes from the Type C meeting in order to finalize the PATHFNDR-2 study protocol and initiate recruitment. We believe
424B5
xsuy73 it
21 Oct 21
Prospectus supplement for primary offering
4:26pm
424B5
1bznaf 5rsy4l5o5
20 Oct 21
Prospectus supplement for primary offering
4:15pm
S-3ASR
ac7f06ezfw7ffhv
10 Aug 21
Automatic shelf registration
5:25pm
8-K
EX-99.1
m0304f1
7 Aug 20
Crinetics Pharmaceuticals Reports Second Quarter 2020 Financial Results
7:30am
424B5
obuao3 ma
15 Apr 20
Prospectus supplement for primary offering
4:16pm
424B5
we69dnxlcshasaf
14 Apr 20
Prospectus supplement for primary offering
4:49pm
8-K
EX-99.1
96u pjze3m
6 Apr 20
Regulation FD Disclosure
4:35pm
10-K
2q5id vhvtr6j
13 Mar 19
Annual report
4:06pm
424B4
pgnsd23qu 9r
18 Jul 18
Prospectus supplement with pricing info
5:27pm